11,714 Shares in Mesoblast Limited (NASDAQ:MESO) Purchased by Pine Valley Investments Ltd Liability Co

Pine Valley Investments Ltd Liability Co acquired a new position in Mesoblast Limited (NASDAQ:MESO) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 11,714 shares of the company’s stock, valued at approximately $80,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in MESO. Chase Investment Counsel Corp bought a new position in Mesoblast in the 1st quarter valued at $298,000. Chapin Davis Inc. boosted its holdings in shares of Mesoblast by 50.0% in the second quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock valued at $102,000 after purchasing an additional 5,000 shares during the period. Perkins Coie Trust Co bought a new position in Mesoblast in the second quarter worth approximately $68,000. Finally, GAMMA Investing LLC raised its position in Mesoblast by 50.1% during the 2nd quarter. GAMMA Investing LLC now owns 4,981 shares of the company’s stock valued at $34,000 after purchasing an additional 1,663 shares in the last quarter. 1.43% of the stock is owned by hedge funds and other institutional investors.

Mesoblast Stock Performance

MESO stock traded up $0.27 during trading on Friday, reaching $6.74. 111,497 shares of the company traded hands, compared to its average volume of 954,734. The company has a market capitalization of $769.56 million, a price-to-earnings ratio of -6.02 and a beta of 3.48. The business has a 50 day simple moving average of $6.84 and a 200 day simple moving average of $5.81. Mesoblast Limited has a 12 month low of $1.61 and a 12 month high of $8.66.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. StockNews.com upgraded Mesoblast from a “sell” rating to a “hold” rating in a research note on Tuesday. Piper Sandler upgraded shares of Mesoblast from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $4.00 to $11.00 in a report on Tuesday, July 23rd. Jefferies Financial Group upgraded shares of Mesoblast from a “hold” rating to a “buy” rating in a research note on Thursday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Mesoblast in a report on Thursday.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.